Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
Status:
Completed
Trial end date:
2010-10-22
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and tolerability, optimal biologic dose, and
pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet
count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.